Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  HIV Infection

  Free Subscription


Articles published in Antivir Ther

Retrieve available abstracts of 87 articles:
HTML format
Text format



Single Articles


    April 2017
  1. LUBEL J, Strasser S, Stuart KA, Dore G, et al
    Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir +/- ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.
    Antivir Ther. 2017 Apr 19. doi: 10.3851/IMP3168.
    PubMed     Text format     Abstract available


  2. TROTTIER B, Lake JE, Logue K, Brinson C, et al
    Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
    Antivir Ther. 2017 Apr 12. doi: 10.3851/IMP3166.
    PubMed     Text format     Abstract available


  3. HANKINS CA, Koulla-Shiro S, Kilmarx P, Ferrari G, et al
    Ending AIDS as a public health threat by 2030: Scientific Developments from the 2016 INTEREST Conference in Yaounde, Cameroon.
    Antivir Ther. 2017 Apr 7. doi: 10.3851/IMP3165.
    PubMed     Text format     Abstract available


  4. VAN LUIN M, Ter Beest G, Wijnberger LE, Swanink CM, et al
    Zidovudine continuous infusion in an HIV-infected pregnant woman with a phobia of swallowing pills.
    Antivir Ther. 2017 Apr 3. doi: 10.3851/IMP3164.
    PubMed     Text format     Abstract available


    March 2017
  5. TATON A, Colson P, Dhiver C, Ruiz JM, et al
    Daclatasvir plasma concentration assessment in HIV-HCV-coinfected real-life patients.
    Antivir Ther. 2017 Mar 31. doi: 10.3851/IMP3163.
    PubMed     Text format    


  6. AGUILERA A, Trastoy R, Barreiro P, Costa JJ, et al
    Decline and changing profile of hepatitis delta among injection drug users in Spain.
    Antivir Ther. 2017 Mar 29. doi: 10.3851/IMP3161.
    PubMed     Text format     Abstract available


  7. AFONSO P, Auclair M, Caron-Debarle M, Capeau J, et al
    Impact of CCR5, integrase and protease inhibitors on human endothelial cell function, stress, inflammation and senescence.
    Antivir Ther. 2017 Mar 28. doi: 10.3851/IMP3160.
    PubMed     Text format     Abstract available


  8. ECKARD AR, Rosebush JC, O'Riordan MA, Graves CC, et al
    Neurocognitive dysfunction in HIV-infected youth: investigating the relationship with immune activation.
    Antivir Ther. 2017 Mar 22. doi: 10.3851/IMP3157.
    PubMed     Text format     Abstract available


  9. OLIVEIRA VH, Wiechmann SL, Narciso AM, Webel AR, et al
    Muscle strength is impaired in men but not in women living with HIV taking antiretroviral therapy.
    Antivir Ther. 2017 Mar 22. doi: 10.3851/IMP3159.
    PubMed     Text format     Abstract available


  10. PETOUMENOS K, Choi JY, Hoy J, Kiertiburanakul S, et al
    CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy.
    Antivir Ther. 2017 Mar 14. doi: 10.3851/IMP3155.
    PubMed     Text format     Abstract available


  11. LALLEY-CHARECZKO L, Clark D, Zuppa AF, Moorthy G, et al
    A case study of chewed Truvada(R) for PrEP maintaining protective drug levels as measured by a novel urine tenofovir assay.
    Antivir Ther. 2017 Mar 6. doi: 10.3851/IMP3151.
    PubMed     Text format     Abstract available


  12. BHAGWAT P, Ofotokun I, McComsey GA, Brown TT, et al
    Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes.
    Antivir Ther. 2017 Mar 1. doi: 10.3851/IMP3148.
    PubMed     Text format     Abstract available


    February 2017
  13. BOESECKE C, Singh GK, Scholten SH, Lutz T, et al
    Telaprevir-containing triple therapy in acute HCV coinfection: The CHAT Study.
    Antivir Ther. 2017 Feb 27. doi: 10.3851/IMP3143.
    PubMed     Text format     Abstract available


  14. BISSIO E, Barbas MG, Kademian S, Bouzas MB, et al
    Prevalence of rilpivirine resistance in people starting antiretroviral treatment in Argentina.
    Antivir Ther. 2017 Feb 24. doi: 10.3851/IMP3147.
    PubMed     Text format     Abstract available


  15. ARENAS-PINTO A, Stohr W, Clarke A, Williams I, et al
    Evaluation of CSF virological escape in patients on long-term PI monotherapy.
    Antivir Ther. 2017 Feb 24. doi: 10.3851/IMP3146.
    PubMed     Text format     Abstract available


  16. TRAN M, Wood E, Kerr T, Patterson S, et al
    Increases in CD4+ T-cell count at antiretroviral therapy initiation among HIV-positive illicit drug users during a treatment-as-prevention initiative in Canada.
    Antivir Ther. 2017 Feb 24. doi: 10.3851/IMP3145.
    PubMed     Text format     Abstract available


  17. BEHM MO, Yee KL, Fan L, Fackler P, et al
    Effect of gender and age on the relative bioavailability of doravirine: results of a Phase I trial in healthy subjects.
    Antivir Ther. 2017 Feb 16. doi: 10.3851/IMP3142.
    PubMed     Text format     Abstract available


  18. KREUTZWISER D, Sheehan N, Dayneka N, Lemire B, et al
    Therapeutic drug monitoring guided raltegravir dosing for prevention of vertical transmission in a premature neonate born to a woman living with perinatally acquired HIV.
    Antivir Ther. 2017 Feb 15. doi: 10.3851/IMP3139.
    PubMed     Text format     Abstract available


  19. MOTTA I, Allice T, Romito A, Ferrara M, et al
    Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia.
    Antivir Ther. 2017 Feb 15. doi: 10.3851/IMP3140.
    PubMed     Text format     Abstract available


  20. BREGIGEON S, Solas C, Faucher O, Obry-Roguet V, et al
    Impact of tenofovir dose adjustment on both estimated glomerular filtration rate and tenofovir trough concentration.
    Antivir Ther. 2017 Feb 14. doi: 10.3851/IMP3137.
    PubMed     Text format     Abstract available


  21. LI Y, Xie J, Wang H, Han Y, et al
    Elevated pre-treatment IL-18 level is associated with HBeAg seroconversion in HIV-HBV coinfection.
    Antivir Ther. 2017 Feb 14. doi: 10.3851/IMP3136.
    PubMed     Text format     Abstract available


  22. COPPOLA N, De Pascalis S, Messina V, Di Caprio G, et al
    ITPase activity modulates the severity of anaemia in HCV-related cirrhosis treated with ribavirin-containing interferon-free regimens.
    Antivir Ther. 2017 Feb 6. doi: 10.3851/IMP3134.
    PubMed     Text format     Abstract available


    January 2017
  23. SQUIQUERA L, Taxman DJ, Brendle SA, Torres R, et al
    Ranpirnase eradicates human papillomavirus in cultured cells and heals anogenital warts in a Phase I study.
    Antivir Ther. 2017 Jan 25. doi: 10.3851/IMP3133.
    PubMed     Text format     Abstract available


  24. PORTER DP, Kulkarni R, Garner W, Miller MD, et al
    Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/ tenofovir DF or efavirenz/emtricitabine/ tenofovir DF through 96 weeks.
    Antivir Ther. 2017 Jan 16. doi: 10.3851/IMP3128.
    PubMed     Text format     Abstract available


  25. MARGOT N, Cox S, Das M, McCallister S, et al
    Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide or elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate.
    Antivir Ther. 2017 Jan 11. doi: 10.3851/IMP3125.
    PubMed     Text format     Abstract available


  26. JOTWANI V, Scherzer R, Estrella MM, Jacobson LP, et al
    Association of HIV infection with biomarkers of kidney injury and fibrosis in the Multicenter AIDS Cohort Study.
    Antivir Ther. 2017 Jan 5. doi: 10.3851/IMP3124.
    PubMed     Text format     Abstract available


  27. JANSSEN S, Huson MA, Osbak KK, Rossatanga EG, et al
    HIV infection rather than concurrent opportunistic infections drives most systemic procoagulant, vascular and damage responses - a prospective cohort study in central Africa.
    Antivir Ther. 2017 Jan 5. doi: 10.3851/IMP3100.
    PubMed     Text format     Abstract available


  28. TEERAANANCHAI S, Chaivooth S, Kerr SJ, Bhakeecheep S, et al
    Life expectancy after initiation of combination antiretroviral therapy in Thailand.
    Antivir Ther. 2017 Jan 5. doi: 10.3851/IMP3121.
    PubMed     Text format     Abstract available


  29. SIMONETTI FR, Cattaneo D, Zanchetta N, Giacomet V, et al
    Pregnancy-related changes of antiretroviral pharmacokinetics: an argument for TDM.
    Antivir Ther. 2017 Jan 4. doi: 10.3851/IMP3122.
    PubMed     Text format     Abstract available


    December 2016
  30. CATTANEO D, Minisci D, Cozzi V, Riva A, et al
    Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
    Antivir Ther. 2016 Dec 23. doi: 10.3851/IMP3119.
    PubMed     Text format     Abstract available


  31. BENOIT AC, Younger J, Beaver K, Jackson R, et al
    A comparison of virological suppression and rebound between Indigenous and non-Indigenous persons initiating combination antiretroviral therapy in a multisite cohort of individuals living with HIV in Canada.
    Antivir Ther. 2016 Dec 7. doi: 10.3851/IMP3114.
    PubMed     Text format     Abstract available


  32. ROCKSTROH JK, Plonski F, Bansal M, Fatkenheuer G, et al
    Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial.
    Antivir Ther. 2016 Dec 7. doi: 10.3851/IMP3116.
    PubMed     Text format     Abstract available


  33. THOMPSON M, Lalezari JP, Kaplan R, Pinedo Y, et al
    Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.
    Antivir Ther. 2016 Dec 6. doi: 10.3851/IMP3112.
    PubMed     Text format     Abstract available


    November 2016
  34. ROCKSTROH JK, Ingiliz P, Petersen J, Peck-Radosavljevic M, et al
    Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
    Antivir Ther. 2016 Nov 15. doi: 10.3851/IMP3108.
    PubMed     Text format     Abstract available


  35. NAICKER N, Naidoo A, Werner L, Garrett N, et al
    Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials.
    Antivir Ther. 2016 Nov 4. doi: 10.3851/IMP3106.
    PubMed     Text format     Abstract available


  36. GILL VC, Lynch T, Ramazani S, Krentz HB, et al
    Reporting on the prevalence of antiretroviral drug resistance in a regional HIV population over 20 years: a word of caution.
    Antivir Ther. 2016 Nov 2. doi: 10.3851/IMP3105.
    PubMed     Text format     Abstract available


    October 2016
  37. SUDJARITRUK T, Bunupuradah T, Aurpibul L, Kosalaraksa P, et al
    Impact of tenofovir disoproxil fumarate on bone metabolism and bone mass among perinatally HIV-infected Asian adolescents.
    Antivir Ther. 2016 Oct 27. doi: 10.3851/IMP3103.
    PubMed     Text format     Abstract available


  38. MATOGA MM, Hosseinipour MC, Aga E, Ribaudo HJ, et al
    Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings.
    Antivir Ther. 2016 Oct 14. doi: 10.3851/IMP3101.
    PubMed     Text format     Abstract available


  39. FUNDERBURG NT, Xu D, Playford MP, Joshi AA, et al
    Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity.
    Antivir Ther. 2016 Oct 14. doi: 10.3851/IMP3091.
    PubMed     Text format     Abstract available


  40. PEREZ-MATUTE P, Pichel JG, Iniguez M, Recio-Fernandez E, et al
    Maraviroc ameliorates the increased adipose tissue macrophage recruitment induced by a high-fat diet in a mouse model of obesity.
    Antivir Ther. 2016 Oct 11. doi: 10.3851/IMP3099.
    PubMed     Text format     Abstract available


  41. RANDELL P, Jackson A, Milinkovic A, Boffito M, et al
    An open-label, randomized study of the impact on insulin sensitivity, lipid profile and vascular inflammation by treatment with lopinavir/ritonavir or raltegravir in HIV-negative male volunteers.
    Antivir Ther. 2016 Oct 6. doi: 10.3851/IMP3098.
    PubMed     Text format     Abstract available


  42. COURNIL A, Hema A, Eymard-Duvernay S, Ciaffi L, et al
    Evolution of renal function in African patients initiating second line antiretroviral treatment: findings from the 2LADY-ANRS 12169 trial.
    Antivir Ther. 2016 Oct 5. doi: 10.3851/IMP3097.
    PubMed     Text format     Abstract available


    September 2016
  43. MAUSS S, Berger F, Wehmeyer MH, Ingiliz P, et al
    Effect of antiviral therapy for HCV on lipid levels.
    Antivir Ther. 2016 Sep 29. doi: 10.3851/IMP3094.
    PubMed     Text format     Abstract available


  44. CAPETTI AF, Orofino G, Sterrantino G, Cossu MV, et al
    Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort.
    Antivir Ther. 2016 Sep 23. doi: 10.3851/IMP3095.
    PubMed     Text format     Abstract available


  45. KELESIDIS T, Tran TT, Brown TT, Moser C, et al
    Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.
    Antivir Ther. 2016 Sep 23. doi: 10.3851/IMP3093.
    PubMed     Text format     Abstract available


  46. PARK MS, Hileman CO, Sattar A, Gilkeson R, et al
    Incidental findings on chest computed tomography are common and linked to inflammation in HIV-infected adults.
    Antivir Ther. 2016 Sep 20. doi: 10.3851/IMP3090.
    PubMed     Text format     Abstract available


  47. TESSON T, Blot M, Fillion A, Djerad H, et al
    Duration of first-line antiretroviral therapy in HIV-infected treatment-naive patients in routine practice.
    Antivir Ther. 2016 Sep 7. doi: 10.3851/IMP3084.
    PubMed     Text format     Abstract available


  48. OLDENBUETTEL C, Wolf E, Ritter A, Noe S, et al
    Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results.
    Antivir Ther. 2016 Sep 2. doi: 10.3851/IMP3082.
    PubMed     Text format     Abstract available


  49. GIROMETTI N, Nwokolo N, McOwan A, Whitlock G, et al
    Outcomes of acutely HIV-1-infected individuals following rapid antiretroviral therapy initiation.
    Antivir Ther. 2016 Sep 2. doi: 10.3851/IMP3080.
    PubMed     Text format     Abstract available


  50. KHELOUFI F, Poizot-Martin I, Garraffo R, Tavenard A, et al
    ITPA deficiency and ribavirin level are still predictive of anaemia in HCV-HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study).
    Antivir Ther. 2016 Sep 1. doi: 10.3851/IMP3074.
    PubMed     Text format     Abstract available


    August 2016
  51. BOYD A, Miailhes P, Lascoux-Combe C, Rougier H, et al
    Renal outcomes after up to eight years of tenofovir exposure in HIV-HBV-coinfected patients.
    Antivir Ther. 2016 Aug 24. doi: 10.3851/IMP3076.
    PubMed     Text format     Abstract available


  52. NAVARRO J, Curran A, Burgos J, Torrella A, et al
    Acute leg ischaemia in an HIV-infected patient receiving antiretroviral treatment.
    Antivir Ther. 2016 Aug 22. doi: 10.3851/IMP3075.
    PubMed     Text format     Abstract available


  53. MAROCCO R, Lichtner M, Tieghi T, Pozzetto I, et al
    Herpes virus reactivation after initiation of interferon-free antiviral agents in HIV-HCV-coinfected subjects: a new immune restoration disease?
    Antivir Ther. 2016 Aug 8. doi: 10.3851/IMP3072.
    PubMed     Text format     Abstract available


    July 2016
  54. BLANCO JR, Jarrin I, Perez-Elias MJ, Gutierrez F, et al
    Combined effect of sex and age in response to antiretroviral therapy in HIV-infected patients.
    Antivir Ther. 2016 Jul 28. doi: 10.3851/IMP3071.
    PubMed     Text format     Abstract available


  55. SHARMA A, Hoover DR, Shi Q, Holman S, et al
    Falls among middle-aged women in the Women's Interagency HIV Study.
    Antivir Ther. 2016 Jul 18. doi: 10.3851/IMP3070.
    PubMed     Text format     Abstract available


    June 2016
  56. D'ALMEIDA KW, Lert F, Spire B, Dray-Spira R, et al
    Determinants of virological response to antiretroviral therapy: socio-economic status still plays a role in the era of cART. Results from the ANRS-VESPA 2 study, France.
    Antivir Ther. 2016 Jun 29. doi: 10.3851/IMP3064.
    PubMed     Text format     Abstract available


  57. BELYHUN Y, Maier M, Liebert UG
    HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia.
    Antivir Ther. 2016 Jun 29. doi: 10.3851/IMP3060.
    PubMed     Text format     Abstract available


  58. ARIAS A, Aguilera A, Soriano V, Benitez-Gutierrez L, et al
    Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
    Antivir Ther. 2016 Jun 24. doi: 10.3851/IMP3061.
    PubMed     Text format     Abstract available


  59. NACCARATO M, Hall E, Wai A, Ostrowski M, et al
    A case of a probable drug interaction between lurasidone and atazanavir-based antiretroviral therapy.
    Antivir Ther. 2016 Jun 22. doi: 10.3851/IMP3059.
    PubMed     Text format     Abstract available


  60. RIVA A, Invernizzi A, Resnati C, Micheli V, et al
    Elvitegravir/cobicistat-associated toxic optical neuropathy in an HIV-infected patient: a call for caution?
    Antivir Ther. 2016 Jun 22. doi: 10.3851/IMP3058.
    PubMed     Text format     Abstract available


    May 2016
  61. ARCHAMPONG TN, Boyce CL, Lartey M, Sagoe KW, et al
    HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
    Antivir Ther. 2016 May 11. doi: 10.3851/IMP3055.
    PubMed     Text format     Abstract available


    April 2016
  62. KEKITIINWA A, Musiime V, Thomason MJ, Mirembe G, et al
    Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children.
    Antivir Ther. 2016 Apr 29. doi: 10.3851/IMP3054.
    PubMed     Text format     Abstract available


  63. ANDRE-GARNIER E, Ribeyrol O, Gournay J, Besse B, et al
    Emergence of HCV resistance-associated variants in patients failing sofosbuvir-based regimens: an observational cohort.
    Antivir Ther. 2016 Apr 29. doi: 10.3851/IMP3053.
    PubMed     Text format     Abstract available


  64. BOETTIGER DC, Khol V, Durier N, Law M, et al
    HIV viral suppression in TREAT Asia HIV Observational Database enrolled adults on antiretroviral therapy at the Social Health Clinic, the National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia.
    Antivir Ther. 2016 Apr 28. doi: 10.3851/IMP3052.
    PubMed     Text format     Abstract available


  65. KAMARA DA, Smith C, Ryom L, Reiss P, et al
    Longitudinal analysis of the associations between antiretroviral therapy, viraemia and immunosuppression with lipid levels: the D:A:D study.
    Antivir Ther. 2016 Apr 26. doi: 10.3851/IMP3051.
    PubMed     Text format     Abstract available


  66. SPINNER CD, Kern KE, Zink A, Wolf E, et al
    Neither boosted elvitegravir nor darunavir with emtricitabine/tenofovir disoproxil fumarate increase insulin resistance in healthy volunteers: results from the STRIBILD-IR study.
    Antivir Ther. 2016 Apr 6. doi: 10.3851/IMP3049.
    PubMed     Text format     Abstract available


  67. CARNOVALI M, Banfi G, Mora S, Mariotti M, et al
    Tenofovir and bone: age-dependent effects in a zebrafish animal model.
    Antivir Ther. 2016 Apr 1. doi: 10.3851/IMP3048.
    PubMed     Text format     Abstract available


    March 2016
  68. DE LA MATA NL, Kumarasamy N, Khol V, Ng OT, et al
    Improved survival in HIV treatment programmes in Asia.
    Antivir Ther. 2016 Mar 10. doi: 10.3851/IMP3041.
    PubMed     Text format     Abstract available


  69. MIKULA JM, Manion MM, Maldarelli F, Suarez LM, et al
    Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir DF-associated renal tubulopathy.
    Antivir Ther. 2016 Mar 8. doi: 10.3851/IMP3040.
    PubMed     Text format     Abstract available


    February 2016
  70. BARREIRO P, Labarga P, de Mendoza C, Benitez-Gutierrez L, et al
    High serum HCV RNA in chronic hepatitis C patients coinfected with HIV despite successful antiretroviral therapy.
    Antivir Ther. 2016 Feb 18. doi: 10.3851/IMP3038.
    PubMed     Text format     Abstract available


  71. GALY A, Ciaffi L, Le Moing V, Eymard-Duvernay S, et al
    Incidence of infectious morbidity events after second-line antiretroviral therapy initiation in HIV-infected adults in Yaounde, Cameroon.
    Antivir Ther. 2016 Feb 16. doi: 10.3851/IMP3030.
    PubMed     Text format     Abstract available


  72. MARTINELLO M, Hellard M, Shaw D, Petoumenos K, et al
    Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies.
    Antivir Ther. 2016 Feb 11. doi: 10.3851/IMP3035.
    PubMed     Text format     Abstract available


  73. NAEGER LK, Harrington P, Komatsu T, Deming D, et al
    Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients.
    Antivir Ther. 2016 Feb 11. doi: 10.3851/IMP3033.
    PubMed     Text format     Abstract available


  74. COUGHLAN R, Cameron S
    Key data from the 17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV.
    Antivir Ther. 2016 Feb 9. doi: 10.3851/IMP3031.
    PubMed     Text format     Abstract available


    January 2016
  75. SHEPHERD L, Borges AH, Ravn L, Harvey R, et al
    Predictive value of prostate specific antigen in a European HIV-positive cohort: does one size fit all?
    Antivir Ther. 2016 Jan 29. doi: 10.3851/IMP3026.
    PubMed     Text format     Abstract available



  76. Systematic review to determine the prevalence of transmitted drug resistance mutations to rilpivirine in HIV-infected treatment-naive persons.
    Antivir Ther. 2016 Jan 13. doi: 10.3851/IMP3024.
    PubMed     Text format     Abstract available


  77. NAVARRO J, Caballero E, Curran A, Burgos J, et al
    Impact of low-level viraemia on virological failure in HIV-1-infected patients with stable antiretroviral treatment.
    Antivir Ther. 2016 Jan 12. doi: 10.3851/IMP3023.
    PubMed     Text format     Abstract available


  78. MEKURIA LA, Nieuwkerk PT, Yalew AW, Sprangers MA, et al
    High level of virological suppression among HIV-infected adults receiving combination antiretroviral therapy in Addis Ababa, Ethiopia.
    Antivir Ther. 2016 Jan 6. doi: 10.3851/IMP3020.
    PubMed     Text format     Abstract available


  79. DUMOND JB, Francis O, Cottrell M, Trezza C, et al
    Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16 expression in subjects on combination therapy.
    Antivir Ther. 2016 Jan 5. doi: 10.3851/IMP3017.
    PubMed     Text format     Abstract available



  80. 18th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV.
    Antivir Ther. 2016;21 Suppl 1:A1-A63.
    PubMed     Text format    


    December 2015
  81. TIRABOSCHI JM, Knobel H, Imaz A, Villar J, et al
    Cerebrospinal fluid and plasma lopinavir concentrations and viral response in virologically suppressed patients switching to lopinavir/ritonavir monotherapy once daily.
    Antivir Ther. 2015 Dec 14. doi: 10.3851/IMP3015.
    PubMed     Text format     Abstract available


    November 2015
  82. AGUERO F, Cofan F, Fortuny C, Lopez M, et al
    Pregnancy in a renal transplant recipient with HIV-1 infection: a case report.
    Antivir Ther. 2015 Nov 18. doi: 10.3851/IMP3013.
    PubMed     Text format     Abstract available


  83. TAMBUYZER L, Thys K, Hoogstoel A, Nijs S, et al
    Assessment of etravirine resistance in HIV-1-infected paediatric patients using population and deep sequencing: final results of the PIANO study.
    Antivir Ther. 2015 Nov 13. doi: 10.3851/IMP3011.
    PubMed     Text format     Abstract available


  84. GAZAIGNES S, Resche-Rigon M, Gatey C, Yang C, et al
    Efficacy and safety of a switch to rilpivirine-based regimens in treatment-experienced HIV-1-infected patients: a cohort study.
    Antivir Ther. 2015 Nov 13. doi: 10.3851/IMP3010.
    PubMed     Text format     Abstract available


  85. NDAHIMANA JD, Riedel DJ, Muhayimpundu R, Nsanzimana S, et al
    HIV drug resistance mutations among patients failing second-line antiretroviral therapy in Rwanda.
    Antivir Ther. 2015 Nov 12. doi: 10.3851/IMP3005.
    PubMed     Text format     Abstract available



  86. Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand.
    Antivir Ther. 2015 Nov 12. doi: 10.3851/IMP3008.
    PubMed     Text format     Abstract available


  87. NON L, Jeroudi A, Smith BT, Parsaei S, et al
    Bull's eye maculopathy in an HIV-positive patient receiving ritonavir.
    Antivir Ther. 2015 Nov 11. doi: 10.3851/IMP3007.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: